Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on September 2, 2015. The report addresses a specific corporate event regarding intellectual property rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a non-financial event and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the issuance of a fifth patent by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR, the company's novel once-daily extended-release oxcarbazepine product.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the patent issuance. The event is presented as a positive development for the company's intellectual property portfolio.
Investor Verification Checklist
- Verify the specific claims and scope of the fifth USPTO patent issued for Oxtellar XR.
- Review the full text of the press release (Exhibit 99.1) for details on the patent's expiration date and coverage.
- Confirm the status of the company's other four existing patents for Oxtellar XR.